Todos Medical Ltd CEO Gerald Commissiong tells Proactive enrollment of the 77-patient, Phase 2, randomized, double-blind, placebo-controlled clinical trial in hospitalized COVID-19 patients has been paused at the two open clinical sites in Israel to allow for an interim analysis of the data.

Following the interim analysis, the company said it will make decisions on the next steps in the clinical development program for Tollovir in COVID-19 for patients who are hospitalized, present with moderate disease, have Long Haulers (Post –Acute Sequelae of SARS CoV-2), and are less than 18 years of age.

https://www.proactiveinvestors.com/companies/...66847.html